![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Paclitaxel: As Adjuvant or Neoadjuvant Therapy in Early Breast Cancer
By Dene Simpson Greg L. Plosker
Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Breast cancer adjuvant therapy use increases in the US
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 367, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Use of LHRH-agonists as adjuvant therapy for breast cancer
By Cuzick Jack
Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 8, 2008-08 ,pp. :